Latest From Xenikos BV
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Western Europe
- Parent & Subsidiaries
- Xenikos BV
- Senior Management
Ypke van Oosterhout, CEO
André de Lege, CFO
Eric van Hooren, Chief Dev. Officer
Maarten Frijlink , COO
- Contact Info
Phone: 23 24 300 100
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.